In Vitro Susceptibility of Characterized β-lactamase-producing Strains Tested with Avibactam Combinations

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2014 Dec 24

PMID 25534728

Citations 57

Authors

Henry Li

Mark Estabrook

George A Jacoby

Wright W Nichols

Raymond T Testa

Karen Bush

Affiliations

Soon will be listed here.

Abstract

Avibactam, a broad-spectrum β-lactamase inhibitor, was tested with ceftazidime, ceftaroline, or aztreonam against 57 well-characterized Gram-negative strains producing β-lactamases from all molecular classes. Most strains were nonsusceptible to the β-lactams alone. Against AmpC-, extended-spectrum β-lactamase (ESBL)-, and KPC-producing Enterobacteriaceae or Pseudomonas aeruginosa, avibactam lowered ceftazidime, ceftaroline, or aztreonam MICs up to 2,048-fold, to ≤4 μg/ml. Aztreonam-avibactam MICs against a VIM-1 metallo-β-lactamase-producing Enterobacter cloacae and a VIM-1/KPC-3-producing Escherichia coli isolate were 0.12 and 8 μg/ml, respectively.

Citing Articles

The in vitro synergistic and antibiofilm activity of Ceftazidime/avibactam against Achromobacter species recovered from respiratory samples of cystic fibrosis patients.

Mataraci-Kara E, Damar-Celik D, Ozbek-Celik B Eur J Clin Microbiol Infect Dis. 2024; 44(3):587-596.

PMID: 39702543 DOI: 10.1007/s10096-024-05017-0.

Prevention and potential remedies for antibiotic resistance: current research and future prospects.

Khan R, Sharma V, Khan S, Rasool S Front Microbiol. 2024; 15:1455759.

PMID: 39421555 PMC: 11484029. DOI: 10.3389/fmicb.2024.1455759.

Dose selection for aztreonam-avibactam, including adjustments for renal impairment, for Phase IIa and Phase III evaluation.

Das S, Riccobene T, Carrothers T, Wright J, MacPherson M, Cristinacce A Eur J Clin Pharmacol. 2024; 80(4):529-543.

PMID: 38252170 PMC: 10937790. DOI: 10.1007/s00228-023-03609-x.

Approaches to Testing Novel β-Lactam and β-Lactam Combination Agents in the Clinical Laboratory.

Russo C, Humphries R Antibiotics (Basel). 2023; 12(12).

PMID: 38136734 PMC: 10740869. DOI: 10.3390/antibiotics12121700.

Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Enterobacterales Analyzed by ICU and Non-ICU Wards, Infection Sources, and Geographic Regions: ATLAS Program 2016-2020.

Pierard D, Hermsen E, Kantecki M, Arhin F Antibiotics (Basel). 2023; 12(11).

PMID: 37998793 PMC: 10668788. DOI: 10.3390/antibiotics12111591.

References

Queenan A, Gold H, Carmeli Y, Eliopoulos G, Moellering Jr R, Quinn J . SME-type carbapenem-hydrolyzing class A beta-lactamases from geographically diverse Serratia marcescens strains. Antimicrob Agents Chemother. 2000; 44(11):3035-9. PMC: 101599. DOI: 10.1128/AAC.44.11.3035-3039.2000. View

Queenan A, Jenkins S, Bush K . Cloning and biochemical characterization of FOX-5, an AmpC-type plasmid-encoded beta-lactamase from a New York City Klebsiella pneumoniae clinical isolate. Antimicrob Agents Chemother. 2001; 45(11):3189-94. PMC: 90802. DOI: 10.1128/AAC.45.11.3189-3194.2001. View

Queenan A, Foleno B, Gownley C, Wira E, Bush K . Effects of inoculum and beta-lactamase activity in AmpC- and extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae clinical isolates tested by using NCCLS ESBL methodology. J Clin Microbiol. 2004; 42(1):269-75. PMC: 321709. DOI: 10.1128/JCM.42.1.269-275.2004. View

Jacoby G, Mills D, Chow N . Role of beta-lactamases and porins in resistance to ertapenem and other beta-lactams in Klebsiella pneumoniae. Antimicrob Agents Chemother. 2004; 48(8):3203-6. PMC: 478483. DOI: 10.1128/AAC.48.8.3203-3206.2004. View

Queenan A, Shang W, Kania M, Page M, Bush K . Interactions of ceftobiprole with beta-lactamases from molecular classes A to D. Antimicrob Agents Chemother. 2007; 51(9):3089-95. PMC: 2043179. DOI: 10.1128/AAC.00218-07. View

Bush K, Flamm R, Ohringer S, Singer S, SUMMERILL R, Bonner D . Effect of clavulanic acid on activity of beta-lactam antibiotics in Serratia marcescens isolates producing both a TEM beta-lactamase and a chromosomal cephalosporinase. Antimicrob Agents Chemother. 1991; 35(11):2203-8. PMC: 245360. DOI: 10.1128/AAC.35.11.2203. View

Jacoby G, Sutton L . Properties of plasmids responsible for production of extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 1991; 35(1):164-9. PMC: 244959. DOI: 10.1128/AAC.35.1.164. View

Louie A, Bied A, Fregeau C, Van Scoy B, Brown D, Liu W . Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance. Antimicrob Agents Chemother. 2010; 54(6):2638-45. PMC: 2876389. DOI: 10.1128/AAC.01721-09. View

Livermore D, Mushtaq S, Warner M, Zhang J, Maharjan S, Doumith M . Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-Producing Enterobacteriaceae. Antimicrob Agents Chemother. 2010; 55(1):390-4. PMC: 3019623. DOI: 10.1128/AAC.00756-10. View

10.

Aktas Z, Kayacan C, Oncul O . In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae. Int J Antimicrob Agents. 2011; 39(1):86-9. DOI: 10.1016/j.ijantimicag.2011.09.012. View

11.

Zhanel G, Lawson C, Adam H, Schweizer F, Zelenitsky S, Lagace-Wiens P . Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs. 2013; 73(2):159-77. DOI: 10.1007/s40265-013-0013-7. View

12.

Sader H, Flamm R, Jones R . Antimicrobial activity of ceftaroline-avibactam tested against clinical isolates collected from U.S. Medical Centers in 2010-2011. Antimicrob Agents Chemother. 2013; 57(4):1982-8. PMC: 3623348. DOI: 10.1128/AAC.02436-12. View

13.

Ehmann D, Jahic H, Ross P, Gu R, Hu J, Durand-Reville T . Kinetics of avibactam inhibition against Class A, C, and D β-lactamases. J Biol Chem. 2013; 288(39):27960-71. PMC: 3784710. DOI: 10.1074/jbc.M113.485979. View

14.

Karlowsky J, Adam H, Baxter M, Lagace-Wiens P, Walkty A, Hoban D . In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance study. Antimicrob Agents Chemother. 2013; 57(11):5600-11. PMC: 3811279. DOI: 10.1128/AAC.01485-13. View

15.

Castanheira M, Farrell S, Krause K, Jones R, Sader H . Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups. Antimicrob Agents Chemother. 2013; 58(2):833-8. PMC: 3910895. DOI: 10.1128/AAC.01896-13. View

16.

Bush K . Carbapenemases: Partners in crime. J Glob Antimicrob Resist. 2016; 1(1):7-16. DOI: 10.1016/j.jgar.2013.01.005. View

17.

OCALLAGHAN C, Morris A, Kirby S, Shingler A . Novel method for detection of beta-lactamases by using a chromogenic cephalosporin substrate. Antimicrob Agents Chemother. 1972; 1(4):283-8. PMC: 444209. DOI: 10.1128/AAC.1.4.283. View

18.

Bradford P, Urban C, Jaiswal A, Mariano N, Rasmussen B, Projan S . SHV-7, a novel cefotaxime-hydrolyzing beta-lactamase, identified in Escherichia coli isolates from hospitalized nursing home patients. Antimicrob Agents Chemother. 1995; 39(4):899-905. PMC: 162650. DOI: 10.1128/AAC.39.4.899. View

19.

Bradford P, CHERUBIN C, Idemyor V, Rasmussen B, Bush K . Multiply resistant Klebsiella pneumoniae strains from two Chicago hospitals: identification of the extended-spectrum TEM-12 and TEM-10 ceftazidime-hydrolyzing beta-lactamases in a single isolate. Antimicrob Agents Chemother. 1994; 38(4):761-6. PMC: 284539. DOI: 10.1128/AAC.38.4.761. View

20.

Jacoby G, Han P . Detection of extended-spectrum beta-lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli. J Clin Microbiol. 1996; 34(4):908-11. PMC: 228915. DOI: 10.1128/jcm.34.4.908-911.1996. View